Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen (ORT-OXI-2009)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01822405 |
|
Recruitment Status : Unknown
Verified March 2013 by Hospital Universitario de Canarias.
Recruitment status was: Recruiting
First Posted : April 2, 2013
Last Update Posted : April 2, 2013
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of the fibrosis.
Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical conditions including the treatment of delayed radiation injuries (soft tissue and bony radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation tissue and produces angiogenesis maintained after use.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fibrosis | Drug: pentoxifylline with tocopherol Other: pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy | Phase 2 |
Patients with head and neck tumors often present superficial radiation induced fibrosis and other late complications of radiotherapy that can seriously affect their quality of life.
The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of the fibrosis.
Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical conditions including the treatment of delayed radiation injuries (soft tissue and bony radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation tissue and produces angiogenesis maintained after use.
Both treatments in combination could produce a synergistic effect because the angiogenesis induced by hyperbaric oxygen therapy allow better access to drugs to the injury. The magnetic resonance, provides data of the fibrosis and other side effects of radiotherapy.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 42 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen |
| Study Start Date : | July 2010 |
| Estimated Primary Completion Date : | July 2013 |
| Estimated Study Completion Date : | July 2013 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Pentoxifylline + Tocopherol
Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
|
Drug: pentoxifylline with tocopherol
Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months |
| Experimental: pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy |
Other: pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy
pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months. Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment. |
- Change in skin fibrosis measured by MRI [ Time Frame: From baseline to 6 month of starting treatment ]The change is calculated as the latest time point (6 months) minus the earliest time point (baseline)
- Clinical assessment of the radiation late (delayed) toxicity for mucosal membranes, salivary glands, larynx and skin by the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale) [ Time Frame: Baseline and 6 months ]The change is calculated as the latest time point (6 months) minus the earliest time point (baseline)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Over 18 years and under 70 years old.
- Patients who have received radiotherapy after being diagnosed with cancer of upper aerodigestive tract, and have skin toxicity grade II or higher.
- Follow-up for at least a year after the radiation treatment is completed.
- Absence of tumor at the time of recruitment.
- Patients with the capacity to give informed consent
Exclusion Criteria:
- Allergy or hypersensitivity to Pentoxifylline or others xanthines, or to Tocopherol (vitamin E).
- Patients taking oral anticoagulants (acenocoumarol, warfarin).
- Known hemorrhagic/coagulation disorder.
- Vitamin K deficiency due to any cause.
- Use of estrogens oral contraceptives.
- Serious bleeding or extensive retinal hemorrhage.
- Ischaemic heart diseases, including recent Myocardial Infarction.
- Serious cardiac arrhythmia.
- Severe liver disease.
- Severe renal failure (creatinine clearance <30 mL/min).
- Hypotension.
- Patients with metal objects or electronic devices such as cardiac pacemakers, artificial heart valves or cochlear implants, or any other contraindication for MRI
- Contraindication for Hyperbaric oxygen therapy.
- Patients with mobility problems.
- Female patients who are pregnant or lactating
- Any other situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822405
| Contact: Claudio Otón, MD | coton@ull.es |
| Spain | |
| Hospital Universitario de Canarias | Recruiting |
| La Laguna, S/C de Tenerife, Spain, 38320 | |
| Contact: Claudio Otón, MD coton@ull.es | |
| Principal Investigator: Claudio Otón, MD | |
| Principal Investigator: | Claudio Otón, MD | Hospital Universitario de Canarias |
| Responsible Party: | Hospital Universitario de Canarias |
| ClinicalTrials.gov Identifier: | NCT01822405 |
| Other Study ID Numbers: |
ORT-OXI-2009 |
| First Posted: | April 2, 2013 Key Record Dates |
| Last Update Posted: | April 2, 2013 |
| Last Verified: | March 2013 |
|
Fibrosis Pathologic Processes Tocopherols Vitamin E Tocotrienols alpha-Tocopherol Pentoxifylline Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors |
Radiation-Protective Agents Protective Agents Physiological Effects of Drugs Vasodilator Agents Free Radical Scavengers Antioxidants Vitamins Micronutrients Nutrients Growth Substances |